Pharmaceuticals in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values refer to the value generated by market players.
The US pharmaceuticals market registered revenues of $496.7 billion in 2023, representing a compound annual growth rate (CAGR) of 0.4% between 2018 and 2023.
In 2023, the US held a 35.9% share of the American pharmaceuticals market.
Scope
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the pharmaceuticals market in the United States
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in the United States
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the United States pharmaceuticals market with five year forecasts
Reasons to Buy
What was the size of the United States pharmaceuticals market by value in 2023?
What will be the size of the United States pharmaceuticals market in 2028?
What factors are affecting the strength of competition in the United States pharmaceuticals market?
How has the market performed over the last five years?
What are the main segments that make up the United States's pharmaceuticals market?
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market rivalry
1.5. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do leading players follow?
7.3. What are the strengths of the leading players?
7.4. What are the recent developments in the market?
8 Company Profiles
8.1. Johnson & Johnson
8.2. AbbVie Inc
8.3. Merck & Co Inc
8.4. Pfizer Inc
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: United States pharmaceuticals market value: $ billion, 2018-23
Table 2: United States pharmaceuticals market geography segmentation: $ billion, 2023
Table 3: United States pharmaceuticals market value forecast: $ billion, 2023-28
Table 4: Johnson & Johnson: Key Facts
Table 5: Johnson & Johnson: Annual Financial Ratios
Table 6: Johnson & Johnson: Key Employees
Table 7: Johnson & Johnson: Key Employees Continued
Table 8: AbbVie Inc: Key Facts
Table 9: AbbVie Inc: Annual Financial Ratios
Table 10: AbbVie Inc: Key Employees
Table 11: AbbVie Inc: Key Employees Continued
Table 12: Merck & Co Inc: Key Facts
Table 13: Merck & Co Inc: Annual Financial Ratios
Table 14: Merck & Co Inc: Key Employees
Table 15: Merck & Co Inc: Key Employees Continued
Table 16: Pfizer Inc: Key Facts
Table 17: Pfizer Inc: Annual Financial Ratios
Table 18: Pfizer Inc: Key Employees
Table 19: Pfizer Inc: Key Employees Continued
Table 20: United States Size of Population (million), 2019-23
Table 21: United States Real GDP (constant 2010 prices, $ billion), 2019-23
Table 22: United States GDP (current prices, $ billion), 2019-23
Table 23: United States Inflation, 2019-23
Table 24: United States Consumer Price Index (absolute), 2019-23
Table 25: United States Exchange Rate, 2018-23
List of Figures
Figure 1: 220 Laboratories Inc: Deal Activity by Deal Type - Volume (2020 - YTD*2024)
Figure 2: 220 Laboratories Inc: Private Equity and Ownership Volume and Value Trend (2020 - YTD*2024)
Figure 3: 220 Laboratories Inc: Private Equity and Ownership Volume by Deal Type (2020 - YTD*2024)